A phase III randomized, double blind trial of LdT (telbivudine) versus lamivudine in Chinese adults with compensated chronic hepatitis B

Trial Profile

A phase III randomized, double blind trial of LdT (telbivudine) versus lamivudine in Chinese adults with compensated chronic hepatitis B

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2015

At a glance

  • Drugs Telbivudine (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Idenix Pharmaceuticals
  • Most Recent Events

    • 01 May 2007 Status changed from in progress to completed
    • 17 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top